Guo H, Wang Y, Zhao Z, Shao X
Department of General Surgery, The Third Affiliated Hospital of Qiqihaer Medical College, Heilongjiang, China.
Scand J Immunol. 2015 Feb;81(2):129-34. doi: 10.1111/sji.12257.
Liver ischaemia/reperfusion injury (IRI) is a serious pathologic process encountered in a number of clinical syndromes including liver transplantation, liver resection, trauma and haemorrhagic shock. Platelet factor 4 (PF4) was the first discovered CXC chemokine and is found in platelet granules at very high concentration. In this study, we provide strong evidence that PF4 is involved directly in liver innate immune response against IRI by regulating Th17 differentiation. PF4 deficiency aggravates liver IRI, as shown by higher serum alanine aminotransferase (ALT) levels and Suzuki scores. PF4 deficiency promotes Th17 response with higher levels of IL-23, IL-6 and IL-17, which aggravates liver IRI. Furthermore, PF4 deficiency limits suppressor of cytokine signalling 3 (SOCS3) expressions, and PF4 fails to suppress expression of IL-17 in cells transfected with SOCS3 SiRNA. In conclusion, PF4 limits liver IRI through IL-17 inhibition via upregulation of SOCS3.
肝脏缺血/再灌注损伤(IRI)是一种在多种临床综合征中出现的严重病理过程,包括肝移植、肝切除、创伤和失血性休克。血小板因子4(PF4)是最早发现的CXC趋化因子,在血小板颗粒中以非常高的浓度存在。在本研究中,我们提供了强有力的证据表明PF4通过调节Th17分化直接参与肝脏针对IRI的固有免疫反应。PF4缺乏会加重肝脏IRI,血清丙氨酸转氨酶(ALT)水平升高和铃木评分升高表明了这一点。PF4缺乏通过更高水平的IL-23、IL-6和IL-17促进Th17反应,从而加重肝脏IRI。此外,PF4缺乏会限制细胞因子信号传导抑制因子3(SOCS3)的表达,并且PF4无法抑制用SOCS3 SiRNA转染的细胞中IL-17的表达。总之,PF4通过上调SOCS3抑制IL-17来限制肝脏IRI。